This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zingo

Marathon Pharmaceuticals LLC

Drug Names(s): lidocaine hydrochloride monohydrate, ALGRX 3268

Description: Zingo is a lidocaine hydrochloride monohydrate powder designed for intradermal administration. Lidocaine is an amide-type local anesthetic that blocks sodium ion channels that are required for the initiation and conduction of neuronal impulses.

Deal Structure: Anesiva and Powder/Lee's Pharmaceuticals
In December 2009, Anesiva sold certain assets related to Zingo to Powder Pharmaceuticals and Lee's Pharmaceuticals. Under the terms of the Asset Purchase Agreement, the total purchase price of the Zingo-related assets was approximately $2.7 million with payment contingent on the delivery of certain assets to Powder Pharmaceuticals and Lee's Pharmaceuticals.

Marathon and Powder/Lee's Pharmaceuticals
In November 2013, Lees Pharmaceutical announced that a License, Distribution & Supply Agreement (Agreement) for Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system has been executed between Powder Pharmaceuticals, an associated company of the Group, and Marathon Pharmaceuticals.

According to the Agreement, Marathon is appointed by Powder as the exclusive licensee, distributor, marketer, advertiser, promoter, importer and seller of Zingo in the United States. The Agreement is effective...See full deal structure in Biomedtracker

Partners: Lee's Pharmaceutical Holdings Limited


Zingo News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug